文献速递血脂与心血管预防

低剂量阿司匹林用于2型糖尿病一级预防心血管事件:随机对照试验10年随访

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
PubMed 文献 · Circulation · 2016-11-15

JPAD试验10年随访纳入2539例无心血管疾病的日本2型糖尿病患者,随机接受阿司匹林81或100 mg/日或不接受阿司匹林。按方案分析显示低剂量阿司匹林未减少心血管事件(HR 1.14;95%CI 0.91-1.42),但胃肠道出血发生率在阿司匹林组更高(2% vs 0.9%,P=0.03)。

要点

  • 低剂量阿司匹林未降低2型糖尿病一级预防患者的心血管事件风险。
  • 阿司匹林组胃肠道出血发生率显著高于无阿司匹林组(2% vs 0.9%,P=0.03)。
  • 出血性卒中发生率两组无差异。

核心结论

  • 在2型糖尿病一级预防人群中,低剂量阿司匹林未影响心血管事件风险,但增加了胃肠道出血风险。

研究设计与样本

  • JPAD试验为随机、开放标签、标准治疗对照试验,纳入2539例无心血管疾病的日本2型糖尿病患者,随机分配至阿司匹林81或100 mg/日组或不接受阿司匹林组。
  • 2008年试验结束后随访至2015年,不改变原分配治疗。
  • 主要分析为按方案队列的心血管事件,安全性分析在意向治疗队列进行。

主要发现

  • 中位随访10.3年,1621例(64%)完成全程随访,2160例(85%)保持原分配。
  • 按方案队列中,低剂量阿司匹林未减少心血管事件(HR 1.14;95%CI 0.91-1.42)。
  • 多变量Cox模型调整年龄、性别、血糖控制、肾功能、吸烟、高血压和血脂异常后结果相似(HR 1.04;95%CI 0.83-1.30),亚组分析无异质性(交互P>0.05)。
  • 意向治疗队列敏感性分析结果一致(HR 1.01;95%CI 0.82-1.25)。
  • 胃肠道出血在阿司匹林组25例(2%),无阿司匹林组12例(0.9%),P=0.03;出血性卒中发生率两组无差异。

关键数值与推荐

  • 低剂量阿司匹林(81或100 mg每日)用于2型糖尿病一级预防未显著降低心血管事件风险(HR 1.14;95%CI 0.91-1.42)。
  • 胃肠道出血发生率阿司匹林组2% vs 无阿司匹林组0.9%(P=0.03)。

临床怎么用

  • 对于无心血管疾病的2型糖尿病患者,不推荐常规使用低剂量阿司匹林进行一级预防,需权衡胃肠道出血风险。

局限性

  • 开放标签设计可能引入偏倚。
  • 仅64%患者完成全程随访,85%保持原分配。
  • 研究人群为日本2型糖尿病患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term efficacy and safety of low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus are still inconclusive. METHODS: The JPAD trial (Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes) was a randomized, open-label, standard care-controlled trial examining whether low-dose aspirin affected cardiovascular events in 2539 Japanese patients with type 2 diabetes mellitus and without preexisting cardiovascular disease. Patients were randomly allocated to receive aspirin (81 or 100 mg daily; aspirin group) or no aspirin (no-aspirin group) in the JPAD trial. After that trial ended in 2008, we followed up with the patients until 2015, with no attempt to change the previously assigned therapy. Primary end points were cardiovascular events, including sudden death, fatal or nonfatal coronary artery disease, fatal or nonfatal stroke, and peripheral vascular disease. For the safety analysis, hemorrhagic events, consisting of gastrointestinal bleeding, hemorrhagic stroke, and bleeding from any other sites, were also analyzed. The primary analysis was conducted for cardiovascular events among patients who retained their original allocation (a per-protocol cohort). Analyses on an intention-to-treat cohort were conducted for hemorrhagic events and statistical sensitivity. RESULTS: The median follow-up period was 10.3 years; 1621 patients (64%) were followed up throughout the study; and 2160 patients (85%) retained their original allocation. Low-dose aspirin did not reduce cardiovascular events in the per-protocol cohort (hazard ratio, 1.14; 95% confidence interval, 0.91-1.42). Multivariable Cox proportional hazard model adjusted for age, sex, glycemic control, kidney function, smoking status, hypertension, and dyslipidemia showed similar results (hazard ratio, 1.04; 95% confidence interval, 0.83-1.30), with no heterogeneity of efficacy in subgroup analyses stratified by each of these factors (all interaction P>0.05). Sensitivity analyses on the intention-to-treat cohort yielded consistent results (hazard ratio, 1.01; 95% confidence interval, 0.82-1.25). Gastrointestinal bleeding occurred in 25 patients (2%) in the aspirin group and 12 (0.9%) in the no-aspirin group (P=0.03), and the incidence of hemorrhagic stroke was not different between groups. CONCLUSIONS: Low-dose aspirin did not affect the risk for cardiovascular events but increased risk for gastrointestinal bleeding in patients with type 2 diabetes mellitus in a primary prevention setting. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00110448.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Saito Y, Okada S, Ogawa H, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2016. PMID: 27881565. doi:10.1161/CIRCULATIONAHA.116.025760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。